cellectis

the life science company



ANNUAL REPORT 2014

Contents

Dear Shareholders,

Over this past year, Cellectis emerged as a key player in the field of immuno-oncology. Very early, we took up the overwhelming challenge of developing best-in-class off-the-shelf engineered CAR T-cell products. Today we are proud to say that significant progress has been made in achieving this objective, as we are getting closer to the clinic.

As a first-mover in this field, Cellectis ranks today among the top leading CAR T-cell companies in the world. At the time, it was ambitious to take on such an endeavor, however we were confident in our skills, expertise and ability to meet our goals.

Cellectis is focused on the development of novel human therapeutics based on its proprietary gene editing technologies. Our most advanced products are adoptive cellular immuno-therapeutics designed to target and eradicate cancer cells. Using our gene editing techniques, these products are the result of genetically modified T-cells to be infused into patients.



Immuno-oncology, which utilizes modified T-cells to fight cancer, is one of the most actively pursued areas of research by academic institutions, biotechnology and pharmaceutical companies. This interest is driven by compelling efficacy data in leukemia with historically bleak outcomes and the potential to achieve a cure, or functional cure, for patients. We are confident that our unique approach represents a promising innovation in this arena.

Our current focus is to develop "off-the-shelf" allogeneic gene-edited T-cell based products. Although a number of companies and academic institutions are pursuing therapies that rely on the patient's own cells to attack his or her cancer, our approach modifies T-cells from healthy donors to target chosen cancer types in any patient. Our T-cells are engineered in a way that prevents them from attacking blindly any tissue of the recipient as non-self. This "Universal" approach represents a groundbreaking advancement from autologous therapies because it is available to any patient, even those who don't have enough T-cells to be treated. In addition, this approach avoids an expensive and time-consuming process of modifying each patient's T-cells on an individual basis. Finally, our T-cells can be shipped worldwide to any clinical cancer center making it available to most patients.

Products currently in development are engineered with TALEN®, a state-of-the-art gene editing technology. Cellectis signed in 2011 an exclusive license from University of Minnesota on TALEN® and in 2014 entered into a non-exclusive license agreement with Thermo Fisher Scientific for its therapeutic uses and with The Two Blades Foundation for its plant activities. The real challenge of gene editing is to precisely and efficiently target a DNA sequence within the genome of a cell with a minimal genotoxicity (off-target). With over 15 years of gene editing, we have developed an unparalleled expertise to edit any gene in a genome in order to disable it, replace it, repair it or insert a new DNA sequence of interest. This is what makes Cellectis such a different company from competition and its product candidates distinctive.

Our T-cell engineering platform that combines CAR with gene editing technologies has enabled us to build a pipeline of allogeneic CAR-bearing, engineered T-cell based (UCART) product candidates. Each of these universal potential products bear different CARs, targeting various tumor-associated antigens, together with a selected set of modifications of the T-cells genome resulting from TALEN®-based gene editing providing to the T-cells new attributes.

During 2014, the Company entered into two significant therapeutic collaboration agreements, reflecting a key facet of the Company's development strategy.

As announced in February 2014, Cellectis signed a collaboration agreement with Servier to develop and market six immuno-adoptive cell therapy drug candidates - including our lead product UCART19 - using engineered T lymphocytes to target leukemias and solid tumors. As part of this agreement, Servier made an initial payment of €7.55 million ($10.3 million).

Upon exercise of each license option provided for in the agreement, Servier will pay a lump sum license fee. Cellectis is eligible to receive aggregate additional payments of up to €813.3 million ($1.11 billion), comprising payments upon the exercise of options granted to Servier under the agreement, and payments upon the occurrence of specified development and commercial milestones. Cellectis is also eligible to receive tiered royalties ranging in the high single-digit percentages based on annual net sales of commercialized products.

Subsequently, in June 2014, Cellectis entered into a research collaboration and license agreement with Pfizer to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology. Today, both companies are working together on preclinical research.
Pfizer has exclusive rights to pursue development and commercialization of CAR-T therapies, in the field of oncology, directed at a total of fifteen targets selected by Pfizer. Pfizer will be responsible for the development and potential commercialization of any CAR-T therapies for the Pfizer-selected targets. In addition, the agreement provides for a total of twelve targets selected by Cellectis. The Company received an upfront payment of $80 million, as well as funding for research and development costs associated with Pfizer-selected targets and four Cellectis-selected targets within the collaboration. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per Pfizer product. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer.

Cellectis is self-developing its own portfolio of CAR-T product candidates, all of them addressing liquid tumors. UCART123 has been designed to address Acute Myeloid Leukemia, UCARTCS1 and UCART38 have been designed to address Multiple Myeloma as well as other indications. We are working on broader sets of undisclosed targets to fight various liquid tumors.

Finally, Cellectis is extremely proud of the outstanding achievements of its plant subsidiary Calyxt based in New Brighton, Minnesota. Calyxt is a unique company developing crops with healthier properties for consumers such as potatoes, soybean oil, wheat or canola. Calyxt's team has achieved in this space more than any large competing organization with the unique goal of bringing, for each of us, better products for a healthier living.

In 2015, Cellectis decided to run an initial public offering on the NASDAQ to further advance its product pipeline. The coming years will be instrumental in turning our product candidates into innovative clinic-ready products. We are all mobilized and we believe we can take on the challenge of working toward our overarching goal of addressing the unmet medical needs of patients.

On behalf of the management team and all Cellectis employees, we would like to thank you for your enduring loyalty and ongoing support.

ANDRÉ CHOULIKA
Chairman and Chief Executive Officer

Cellectis
in brief

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in the field of gene editing - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering gene editing technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets.
Calyxt, Inc. (previously Cellectis plant sciences, Inc.) is a wholly owned subsidiary based in New Brighton, Minnesota. The company aims to create healthier crop products such as low trans fat soybean oil, cold storable potato, gluten reduced wheat and low saturated canola oil for the food and agriculture industries.

Milestones

1999: Cellectis is founded

2005: Development of a process for the industrial production of nucleases

2007: Listing on the Alternext market in Paris

2008 – 2010: Acquisition of technologies and establishment of subsidiaries

2010: Acquisition of all assets of CytoPulse Inc., based in Maryland

The acquisition included Hybrimune electrofusion technology and PulseAgile technology for RNA transfection by electroporation. PulseAgile is now the standard technology for RNA transfection of T-cells.

2010: Founding of Cellectis plant sciences (now Calyxt)

2011: Cellectis acquires exclusive licence to TAL Effector patents from University of Minnesota

2014: Strategic collaboration agreement with Servier

In February, Cellectis and Servier announce collaboration in allogeneic cell therapy to develop and commercialize novel product candidates targeting leukemia and solid tumors.

2014: Cellectis and Thermo Fisher Scientific enter into agreements covering the uses of TAL nucleases under the brand name TALEN®

2014: Global strategic cancer immunotherapy collaboration with Pfizer

In June, Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration to develop immunotherapies against select targets in the field of oncology.

Legal form: French *Société anonyme* with board of directors

Number of shares outstanding at December 31, 2014: 29,419,721
Share capital at December 31, 2014: €1,470,986.05
Market capitalization at December 31, 2014: €340M

Contact

Cellectis, Inc. - 430 East 29th Street - New York,
NY 10016 - USA
P: +1 347 809 5980
Cellectis SA - 8 rue de la Croix Jarry – 75013 Paris – France
P: +33 (0)1 81 69 16 00
e-mails : investors@cellectis.com
www.cellectis.com
Cellectis securities services:
Société Générale Securities Services (affiliate 042)
Citi – Depositary Receipt Services

Intellectual Property: As of March, 2015, we own 87 patent families (consisting of approximately 51 issued patents and an additional 155 patent applications) and have in-licensed an additional 29 patent families. Our intellectual property portfolio provides significant protections over our product candidates and proprietary technology platforms.
We also own trademarks such as Cellectis®, TALEN® and Calyxt™.

Listing markets:

Nasdaq Global Market, New York – Ticker: CLLS

Alternext, Paris – Ticker: ALCLS.PA

2014 highlights

Company Reorganization

January 7th
Cellectis reorganizes its Tools and Services business line, in partnership with Caisse des Dépôts, by contributing Ectycell's shares to Cellectis bioresearch.

July 29th
Cellectis sells its Swedish subsidiary, Cellectis AB, to Takara Bio Inc.

Agreements

January 30th
Precision BioSciences and Cellectis SA announce cross-license and settlement agreement for meganuclease technology.

June 5th
Cellectis and Thermo Fisher Scientific enter into agreements on TALEN®, a leading gene-editing technology.

Patents

February 5th
U.S. Patent Institutions recognize the patentability of Institut Pasteur/Cellectis early inventions on Meganucleases.

May 19th
TAL-effector nuclease: The USPTO issues a fourth patent licensed to Cellectis.

November 4th
TALEN® technology: Grant of EP 2 510 096 by the European Patent Office.

Our Therapeutic Strategy and Partnerships

February 17th
Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors.

June 5th
Cellectis and Accelera (Nerviano Medical Sciences Group) sign an agreement to complete preclinical studies of Cellectis' lead product candidate UCART19.

June 9th
Cellectis enters into an agreement with CELL*for*CURE for the cGMP manufacturing of allogeneic CAR T-cells.

June 18th
Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration.

June 23rd
Cellectis' UCART19 receives Advanced-Therapy medicinal Product classification from EMA.

September 2nd
Cellectis hosts a R&D/Analyst day in New York City.

Financing

March 25th
Cellectis receives €20.5M in commitments in private placement from U.S. biotechnology specialist institutional investors, led by OrbiMed Advisors.

July 31st
Acquisition of an approximate 10% stake in the capital of Cellectis SA by Pfizer with $25.8M in gross proceeds.

November 12th
Cellectis receives proceeds of €13M through the exercise of warrants.

Calyxt (previously Cellectis plant sciences)

May 23rd
Cellectis plant sciences reports generation of High Oleic Soybean in Journal of Plant Biotechnology.

December 18th
Cellectis plant sciences and Two Blades Foundation announce the execution of a cross-license agreement on TAL Effector Nuclease technologies (TALEN®).

Therapeutic activities

INTRODUCTION

Cellectis is a pioneering gene-editing company, employing core proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology. Our product candidates, based on gene-edited T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancers. A key to this effort is a type of white blood cell known as the T-cell, which plays an important role in identifying and killing cancer cells. Unfortunately, cancer cells often develop mechanisms to evade the immune system. CARs, which are engineered receptors that can be expressed on the surface of the T-cell, provide the T-cell with a specific targeting mechanism, thereby enhancing its ability to seek, identify, interact with and destroy tumor cells bearing a selected antigen.

Cellectis is designing next-generation immunotherapies that are based on gene-edited CAR T-cells. Our gene-editing technologies allow us to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves. Gene editing is a type of genetic engineering in which DNA is inserted, deleted, repaired or replaced from a precise location in the genome. The most fundamental challenge of gene editing is the need to specifically and efficiently target a precise DNA sequence within a gene. Our proprietary nuclease-based gene-editing technologies, combined with 15 years of gene editing experience, makes it possible to edit any gene with highly precise insertion, deletion, repair and replacement of DNA sequences. Our nucleases, including a particular class of proteins derived from transcription activator-like effectors act like DNA scissors to edit genes at precise target sites and allow us to design allogeneic CAR T-cells.

Our gene-editing expertise also enables us to develop product candidates that feature additional safety and efficacy attributes, including control properties designed to prevent them from attacking healthy tissues, to enable them to tolerate standard oncology treatments, and to equip them to resist mechanisms that inhibit immune system activity.

ENGINEERED CAR T-CELLS: KEY CONCEPTS

The immune system

The immune system has evolved to protect the body from invading pathogens or external harmful materials by identifying these foreign bodies through "non-self" antigens, which are molecular signatures that they carry and are foreign to the body. A central function of the immune system is to discriminate between "self," which is recognized through antigens normally present in the body and borne by cells, proteins, sugars or lipids, and "non-self", which is detected through abnormal or foreign antigens. Cancer cells thrive, in part, because they trick the immune system into treating them as self, even though they express abnormal antigens, and thus immune tolerance occurs when the immune system fails to recognize and attack tumors. Breaking immune tolerance is an important aspect of most immuno-oncology-based therapeutics because it enables the immune system to recognize and treat tumors as non-self and lead to tumor destruction.

The Chimeric Antigen Receptors or CARs

CARs are engineered molecules that, when present at the surface of T-cells, enable them to recognize specific proteins or antigens that are present on the surface of other cells. These receptors are typically used to graft the specificity of an antibody derived from a single cell, or a monoclonal antibody, onto a T-cell and provide it with a specific targeting mechanism to seek, identify, interact with and destroy the tumor cells bearing a selected antigen associated with that tumor also known as the tumor-associated antigen, or TAA.

Gene editing

The principle of gene editing is simple: it involves modifying the genetic code of an individual or species for the purposes of understanding the way it works, producing useful proteins or treating a disease. Genetics has demonstrated the link between the physical attributes of species and their genes, and thereby shown how particular genes are implicated in certain diseases or attributes. Gene editing enables species' genes to be modified in order to change certain attributes, to correct an error, or to add a new trait of physiological or economic interest.

There are three strategies regarding gene editing:

- Insertion is used to add a new attribute to the genome, for example to overcome a genetic defect.
- Correction is used to replace an existing defective sequence (which generally impacts the gene's functions) by a functional sequence.
- Inactivation is used to prevent the expression of a gene.



The mechanism by which a CAR T-cell attacks a tumor cell



The mechanism by which TALEN® inactivates, or knocks out, a gene

Manufacturing

Our manufacturing process produces UCART products from healthy, tested and qualified donor T-cells. That could contribute designing a product at lower costs. Moreover, because our process is powered by our nucleases and our proprietary PulseAgile electroporation technologies, we expect to be able to inactivate genes in a highly efficient manner that avoids harming T-cells during processing, which could allow us to manufacture quality UCART products at high yields. This could enable us to manufacture in bulk, and we expect that T-cells from one healthy donor, and one manufacturing run of UCART, could be used to create 500-1,000 doses of product. These efficiencies could reduce costs to patients and produce competitive gross profit margins.

Manufacturing Process Platform: Designed for cGPM Compatibility



OUR TECHNOLOGIES

Engineered CAR T-Cells

Cellectis' therapeutics programs are focused on developing products using our gene-editing platform to develop genetically modified T-cells that express a Chimeric Antigen Receptors (CAR) and are designed to target and kill cancer cells. CARs are artificial molecules that, when present at the surface of immune effector cells, will enable them to recognize a desired protein, or antigen, and trigger the killing of cells harboring this antigen at their surface (target cells). Immune cells -most usually T-lymphocytes- can be engineered to express a CAR able to recognize proteins present at the surface of cancer cells. Upon cell-to-cell contact between effector and targeted cells, antigen recognition will activate the effectors, giving them the signal to attack their targets, and leading ultimately to the killing of cancer cells.



Sharpening the power of CAR T-Cells by editing the genome

UCARTs

Our lead immuno-oncology product candidates, which we refer to as UCARTs, are all allogeneic CAR T-cells engineered to be used for treating any patient with a particular cancer type. Each UCART product candidate targets a selected tumor antigen and bears specific engineered attributes, such as compatibility with specific medical regimens that cancer patients may undergo. UCART is our first therapeutic product line that we are developing with our gene-editing platform to address unmet medical needs in oncology.

UCART (Universal Chimeric Antigene Receptor - T-cells) are "off-the-shelf" allogeneic products, whose production can be industrialized and thereby standardized with consistent pharmaceutical release criteria, over time and from batch to batch.

TALEN®: Leading Proprietary Gene-editing Technology

The flagship nuclease structure we use for gene editing is based on a class of proteins derived from transcription activator-like effectors, or TALE.
TALEN® products are designed by fusing the DNA-cutting domain of a nuclease to TALE domains, which can be tailored to specifically recognize a unique DNA sequence. These fusion proteins serve as readily targetable "DNA scissors" for gene editing applications that enable us to perform targeted genome modifications such as sequence insertion, deletion, repair and replacement in living cells.

TALEN® is a registered trademark owned by the Cellectis Group.



Structure of a TALEN®

PulseAgile: Electroporation Technology

In September, 2010, Cellectis has acquired all the assets of Cyto Pulse Sciences Inc., a Maryland-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment.

In order to perform gene editing, we use our proprietary PulseAgile electroporation technology to introduce nucleases inside the target T-cell where they can access the cell's genomic DNA.

Electroporation allows messenger RNA, or mRNA, molecules coding for the nuclease to enter into the cell, where it is translated into the nuclease protein that can cut into the cell's genomic DNA. The mRNA molecules are rapidly degraded by the cell, which means that the nuclease is only expressed for a short time.

PulseAgile electroporation uses a unique electrical field wave-form that, in combination with a proprietary buffer solution, enables molecules, such as nucleases, to enter efficiently into the cell while maintaining a high percentage of viable cells. PulseAgile technology is particularly effective due to the shape of the electrical field that includes high voltage peaks, which are optimized to create transient holes in the cell membrane, followed by lower voltage pulses that help mRNA migrate into the cells. In addition, PulseAgile is optimized to preserve high cell viability and thus suited for large-scale manufacturing. For example, T-cells that undergo TALEN® encoding mRNA electroporation maintain cell viability of approximately 90%.

ENTERING INTO AN AGREEMENT WITH SERVIER IN FEBRUARY 2014

Cellectis entered into a Research, Product Development, Option, License and Commercialization Agreement with Servier, the first French independent pharmaceutical group. The partnership covers the development and potentially the commercialization of Cellectis' lead product candidate, UCART19, as well as five other product candidates targeting solid tumors. Pursuant to this agreement, Cellectis is responsible for the research and development of UCART19 product candidate, including the Phase 1 clinical trial. Cellectis is similarly responsible for the research and development of five additional product candidates consisting of allogeneic antitumor adoptive T-cells directed against particular targets selected by Servier.

Servier may exercise an exclusive worldwide option for a license on each product candidate developed under the agreement. Upon exercising each option, Servier will be responsible for taking over clinical development, registration and commercialization of each product.

Pursuant to the agreement, Servier made an initial payment of €7.55 million ($10.3 million) and, upon its exercise of each license option provided for in the agreement, Servier will pay a lump sum license fee. Cellectis is eligible to receive from Servier aggregate additional payments of up to €813.3 million ($1.11 billion), comprising payments upon the exercise of options granted to Servier under the agreement and payments upon the occurrence of certain specified development and commercial milestones. Cellectis is also eligible to receive tiered royalties ranging in the high single-digit percentages based on annual net sales of commercialized products.

« Through this partnership, Servier is reinforcing its commitment to provide innovative therapeutic solutions for unmet needs in patients with serious illnesses. »

Emmanuel Canet, Ph.D., President of Servier R&D

« These original cell-based therapies will well complement Servier's innovative clinical oncology pipeline , which currently includes immunotherapeutic monoclonal antibodies, an HDAC inhibitor, kinase inhibitors, antiangiogenic and proapoptotic small molecules. »

Jean-Pierre Abastado, Ph.D., Head of the Oncology Innovation Center at Servier

« Our alliance with the Servier Research Group is a real recognition of the value of our innovative approach to treating cancer. Combining Cellectis' technical expertise with Servier's scientific, medical and financial resources will create an exciting new alliance to fuel the development of our unique, novel allogeneic cancer therapies, ultimately benefitting many patients around the world. »

Mathieu Simon, MD, EVP, Chief Operating Officer at Cellectis

ENTERING INTO A COLLABORATION AGREEMENT WITH PFIZER IN JUNE 2014

Cellectis entered into a strategic research collaboration with Pfizer to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology. Under the terms of the agreement, Pfizer has exclusive rights to pursue development and commercialization of CAR-T therapies, in the field of oncology, directed at a total of fifteen targets that it has selected. Both companies will work together on preclinical research and Pfizer will be responsible for the development and potential commercialization of any CAR-T therapies for the Pfizer-selected targets.

The agreement also provides for a total of twelve targets selected by Cellectis. Both companies will work together on preclinical research on four Cellectis-selected targets and Cellectis will work independently on eight additional targets. Cellectis will be responsible for clinical development and commercialization of CAR-T therapeutics for the Cellectis-selected targets. Pfizer has right of first refusal to the four Cellectis-selected targets.

Cellectis received an upfront payment of $80 million, as well as funding for research and development costs associated with Pfizer-selected targets and the four Cellectis-selected targets within the collaboration. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per Pfizer product. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer.

« We believe our CAR-T platform technology has the potential to offer a real advantage over other approaches to T-cell receptor engineering and this collaboration with Pfizer is an important step towards realizing the full potential of this technology in harnessing the body's own immune system to fight cancer. This alliance provides access to Pfizer's state-of-the-art therapeutic development capabilities and provides a unique opportunity to advance this innovative work with the goal of developing best-in-class CAR-T therapeutics. »

André Choulika, Ph.D., Chairman and Chief Executive Officer at Cellectis

« This leading immuno-oncology collaboration aimed at delivering immunotherapies is built upon Cellectis' advanced genome editing and cell engineering capability and Pfizer's cutting-edge biotherapeutic cancer therapy platform. Combining the innovation and scientific expertise of Cellectis with Pfizer's deep oncology and immunology experience creates a world-class partnership designed to deliver a new generation of CAR-T immunotherapies for cancer patients with urgent medical needs. »

Mikael Dolsten, MD, Ph.D., President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc.

THERAPEUTIC PRODUCTS

Pipeline

Our lead immuno-oncology product candidates

Product name Targeted Indication	Discovery	Product development	*In Vitro* Studies	*In Vivo* Studies	CTA/IND filing	Alliance
UCART19 Acute Lymphoblastic Leukemia (ALL) Chronic Lymphocytic Leukemia (CLL)					2015	Servier
UCART123 Acute Myeloid Leukemia (AML)						Wholly-Owned
UCART38 Multiple Myeloma (MM)				Q4 2015		Wholly-Owned
UCARTCS1 Multiple Myeloma (MM)				Q4 2015		Wholly-Owned

Product candidates

UCART19

UCART19 is a potential best-in-class allogeneic engineered T-cell product for treatment of CD19 expressing hematologic malignancies, initially developed in Chronic lymphocytic leukemia (CLL) and Acute lymphoblastic leukemia (ALL). Servier has an option under the collaboration agreement to acquire the exclusive rights to further develop and commercialize UCART19. Engineered allogeneic CD19 T-cells currently stand out as a real therapeutic innovation for treating various types of leukemia and lymphoma. Cellectis' approach with UCART19 is based on the preliminary positive results from clinical trials using products based on the CAR technology and has the potential to overcome the limitation of the autologous current approach by providing an allogeneic frozen, "off the shelf" T-cell based medicinal product.

UCART123

UCART123 is an allogeneic engineered T-cell product designed for the treatment of hematologic malignancies expressing the interleukin-3 low affinity receptor, or CD123, that develop in Acute Myeloid Leukemia (AML). UCART123 is at a preclinical stage of development.

UCART38 and UCARTCS1

UCARTCS1 and UCART38 are allogeneic engineered T-cell products designed for the treatment of CS1-expressing or CD38-expressing hematologic malignancies which develop in multiple myeloma (MM). UCARTCS1 and UCART38 are in discovery stage and have not yet entered into preclinical studies. We plan on advancing the development of these two products through preclinical studies in late 2015 and early 2016. CD38 will be secondarily also developed in ALL and Mantle cell lymphoma (MCL).

Development of a product candidate takes place in several stages:

Discovery
Identification of a new potential target which could lead to a future product candidate.

Product development
Engineering of "Chimeric Antigen Receptor" (CAR) T-cell is the technology developed by Cellectis to construct new potential products. This approach allows Cellectis to develop allogeneic products through a gene-editing mechanism of T-cells derived from healthy donors. Gene editing is performed using TALEN®, which allow very precise and targeted gene modification and provide new attributes to the product such as compatibility with the standard of care.

***In Vitro* Studies**
Studies performed on specific cell lines to have some preliminary results on the activity of a potential product candidate.

***In Vivo* Studies**
Preclinical studies performed on animal models in order to have preliminary results on the dose-dependent toxicity and on the activity of a potential product candidate to validate clinical trials before its investigation.

CTA/IND filing
The Clinical Trial Application (CTA) or the Investigational New Drug (IND) filing in the USA (FDA) is the regulatory step consisting on the submission of the required study documentation package to the health authority to obtain the authorization to perform clinical investigation.


calyxt
Previously Cellectis plant sciences

CALYXT IN BRIEF

Founded in 2010, Calyxt (previously Cellectis plant sciences) is based in New Brighton, Minnesota. The company is an agricultural biotechnology company focused on developing crops with healthier characteristics. Capitalizing on its team and new technologies, the company's mission is to develop a novel generation of crops that will help in producing food products with more health benefit for consumers. Our business philosophy is to focus on developing products and maximizing value through partnerships. Calyxt is involved in a network of collaborations that include global seed companies (Bayer, Limagrain, Monsanto, SESVanderhave among others), as well as leading Healthcare (Mitsubishi Tanabe) and food companies. Calyxt is developing innovative products with prominent partners in order to secure access to the market.

Calyxt's activities are focused in three main areas:

- Developing a pipeline of 3 key crops: potato, wheat and soybean
- Developing a portfolio of traits in various crops such as soybean, rice, corn and canola
- Co-developing products with purchasers.

Our motto:

"Healthier Food for a Better Life"

Milestones

2010: Cellectis plant sciences (now Calyxt) is founded

2011: Cellectis acquires exclusive license to TAL Effector patents from University of Minnesota

2012: Developing partnerships

- Cellectis plant sciences and Bayer CropScience strengthen gene editing partnership
- Medicago and Cellectis enter into research agreement to improve therapeutic proteins using nuclease technology
- Cellectis plant sciences announces the signature of a strategic partnership with SESVanderHave in sugar beet

2014:

- Cellectis plant sciences and Bayer CropScience extend their partnership to improve crops by gene editing
- Cellectis plant sciences reports generation of high oleic soybean in Journal of Plant Biotechnology
- Cellectis plant sciences reports improvement of oil content in algae
- Cellectis plant sciences and Two Blades Foundation announce the execution of a cross-license agreement on TAL Effector Nuclease technologies

Legal Form:

Calyxt is a U.S. incorporated company wholly owned by Cellectis S.A.

Contact

Calyxt, Inc.
600 County Road D W.
Suite 8
New Brighton, MN 55112
P: +1 (651) 683-2807
contact@calyxt.com

www.calyxt.com

CALYXT'S VISION

As the global population continues to increase, so does the global food market. By leveraging our plant-engineering platform and the transformative potential of gene editing, we aim to create food products with consumer health benefits, adaptations for climate change or nutritional enhancements that address the needs of a growing population.

The process used to develop products - Green Evolution - is based on technologies (such as TALEN®) invented by the scientists of the company, widely adopted by the scientific community worldwide and exclusively licensed to Cellectis. Several governmental agencies have indicated that products created by Green Evolution would be regulated as mutagenesis on a product by product basis. The expertise and commercial network includes a range of high value plants: soybean, tobacco, potato, rapeseed, wheat and rice, and can be adjusted to virtually any crop on a need basis.
The high-potential of Calyxt activities and products opens up the prospective of a significant growth and a significant increase in value over the next few years as a result of the first traits being validated in field trials (in-house or with partners).

Reduced trans fat soybean oil

For many food applications, standard soybean oil needs to undergo various processing steps; specifically, soybean oil is hydrogenated to improve heat stability and shelf life, but this process also increases the amount of saturated fatty acids and creates trans-fats, which have been linked to numerous human health issues such as cardiovascular problems. Calyxt has created a non-GM variety of soybean that has high oleic acid and low linoleic acid content, eliminating the need for hydrogenation.

Improved quality potato

Potatoes harvested are cold-stored to ensure a continuous supply line throughout the year; during this cold-storage, starch is converted into reducing sugars. Once these cold-stored potatoes are cooked at temperatures above 250°F the free amino acids and reducing sugars interact to form acrylamide, which is considered as 'probable human carcinogen' by the National Toxicology Program and the International Agency for Research on Cancer, and 'resulted in neurotoxic effects' according to the US Environmental Protection Agency, based on studies in laboratory animals. At Calyxt, we have inactivated the enzyme responsible for the degradation of sugars in the tuber, thus reducing both the sweetening of cold-stored potatoes and the creation of acrylamide during frying.

Lower saturated canola oil

Canola is an important oil crop with approximately 65 million tons produced annually worldwide, making canola the third largest source of vegetable oil in the world. This high demand is driven by the potential health benefits the oil endows, due to the lowest levels of saturated fatty acids among all edible oils. Calyxt is developing a new variety of canola that produces oil with less than 3.5% saturated fat by deactivating one enzyme responsible for the synthesis of saturated fatty acids.

Gluten reduced wheat

A key component of wheat is gluten. It gives elasticity to dough, helping it rise and keep its shape and often gives texture to the final product. Gluten in wheat can be responsible for an adverse immune system reaction. The reaction generally causes inflammation of the small intestine, which interferes with the absorption of nutrients. Calyxt is working to remove the components of gluten responsible for the harmful immune reaction.

Pipeline

Product	Trait	Discovery	Estimated Field Trial			
Soybean	Low trans fat	Done	2015			
	Low linolenic oil	Ongoing		2016		
	Low transfat/low linolenic oil stack	Ongoing			2017	
	Protein content	Ongoing			2017	
Potato	Cold storage	Done	2015			
	Browning reduction	Ongoing		2016		
	Cold storage/Browning reduction stack (fries variety)	Ongoing				2018
	Cold storage/Browning reduction stack (chips variety)	Ongoing				2018
Canola	Improved oil	Ongoing		2016		
	Nitrogen use efficiency	Ongoing				2018
Wheat	Low gluten	Ongoing			2017	

Management team

Dr Luc Mathis, Chief Executive Officer
Luc Mathis earned his Ph.D. in Paris (Institut Pasteur) and completed a post-doctoral fellowship at the California Institute of Technology. He began his career as group leader on the developmental biology and genetics of neural stem cells at the Institut Pasteur with a tenure-track position. He joined Cellectis in 2006 in business development for various R&D markets before joining and co-founding Calyxt.

Dr Dan Voytas, Chief Science Officer
Dan Voytas graduated from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He conducted post-doctoral research at Johns Hopkins University School of Medicine where he was a fellow of the Life Science Research Foundation. In 1992, Dr Voytas joined the faculty at Iowa State University. He was promoted to Associate Professor in 1997 and to Professor in 2001. In 2008, he joined the faculty in the Department of Genetics, Cell Biology and Development at the University of Minnesota (UMN) and he is Director of the UMN's Center for gene editing. He is a co-founder of Calyxt.

Dr Feng Zhang, Chief Operations Officer
Feng Zhang obtained his Ph.D. from Iowa State University working on maize genetics and received post-doctoral training at the University of Georgia with Dr Sue Wessler. He is the co-inventor of more than 10 patents and patent applications. Before joining Calyxt, he co-invented TALEN® technology with Dr Dan Voytas at the University of Minnesota and Dr Adam Bogdanove at Iowa State University. Dr Zhang joined Calyxt in 2010 to develop and lead the trait development programs for crops and vegetables.

Dr William Haun, Director of Product Development
William Haun earned a B.S. and M.S. in Agronomy, Plant Breeding and Plant Genetics from the University of Wisconsin-Madison and a Ph.D. and post-doctoral training in Plant Biology and Genetics from the University of Minnesota. He joined Calyxt in May 2010, setting up the transformation platform and launching some of the company's first projects. He moved into a business development role in January 2013, and now focuses on commercializing the company's first products and building relationships with partners for product development.

Financial Statements

TUNED IN WITH OUR SHAREHOLDERS

During 2014, the value of Cellectis shares increased more than 400%. This increase reflects the relevance of the strategy implemented by company management since 2012. The company has made good use of its expertise in gene editing for the benefit of its therapeutic programs and its agro-industrial activities. By concentrating its activities in the oncology field via the development of drug candidates from engineered T-cells, both alone and in partnership with Servier and Pfizer, Cellectis has succeeded in becoming a key player in the immunotherapy field.

During the past year, Cellectis has kept its shareholders informed and maintains a dialog with them. In March 2014, the company put its new bilingual website online, with two types of access, by menu and by profiles (shareholder, investor, scientist, journalist, candidate), to enable fast access to the desired contents and documents. We thank the many shareholders who expressed their satisfaction after this new tool was launched.

On March 25, Cellectis received commitments for a capital increase of €20,520,000 from U.S. biotechnology institutional investors. The financing was led by OrbiMed Advisors and included venBio, Ridgeback Capital Management, Aquilo Capital Management and Merlin Nexus, among others.

Two Shareholders' General Meetings were held. The Combined General Shareholders' Meeting of June 27 was the occasion for Dr André Choulika, Chairman and Chief Executive Officer of Cellectis, to explain the company's positioning in the field of oncology. To this end, André Choulika sought to put into perspective the various agreements formalized since the beginning of the year.

On July 31, an Extraordinary General Meeting was held to decide on a capital increase to the benefit of Pfizer, for a total amount of 25,779,047 euros. This equity investment – for about 10% of the capital of Cellectis SA – by Pfizer was part of the agreement signed on June 18, 2014 between the two companies forming the framework for their collaboration. The capital increase vote received 100% approval.

Cellectis also held a meeting dedicated to individual shareholders at the company head office on Thursday, October 23. Around 50 people attended this meeting, during which Dr André Choulika, Dr Mathieu Simon, Executive Vice President and Chief Operating Officer, Dr Luc Mathis, CEO of Calyxt (formerly Cellectis Plant Sciences) and Thierry Moulin, Chief Financial Officer, presented the Company and more particularly the therapeutic programs in development, the Calyxt subsidiary, and the interim financial statements at June 30, 2014. This meeting permitted the questions of the shareholders present and those sent by e-mail to be answered.

In 2014, the group issued 36 press releases, or an average of one every 10 days. In addition to regulatory financial publications, these press releases reported on the events that marked Cellectis' life.

The summarized financial statements included in this document are derived from the Group's consolidated financial statements, which are prepared in accordance with IFRS. The consolidated financial statements for the year ended December 31, 2014 were approved by the Board of Directors at its meeting on March 3, 2015 and have been certified without qualification by the Group's Statutory Auditors.
As part of the process to conduct a registered initial public offering in the United States, we performed a review of certain accounting principles which were applied during the first semester of 2014, and during 2013 and the prior years. This review led to modify the application of these methods from January 1, 2014 and to retrospectively book a correction of previously issued financial statements for the first half of 2014 and for the years 2013 and 2012.
On August 29, 2014, we finalized the sale of our subsidiary Cellectis AB. As a consequence, the data presented does not include the figures related to this company which was classified as a discontinued operation. For 2014, the loss from the activities of discontinued operations combines the operating loss of Cellectis AB and the result of its sale.

Balance sheet – Assets

In thousands of euros	December 31, 2014	December 31, 2013
Intangible assets [1]	1,026	4,627
Property, plant and equipment [1]	2,610	3,869
Financial assets	1,977	435
Non-current assets	**5,613**	**8,931**
Inventories	135	367
Operating receivables [2]	19,519	12,018
Cash and cash equivalents [3]	112,347	7,559
Current assets	**132,001**	**19,944**
TOTAL ASSETS	**137,614**	**28,875**

(1) The decrease of intangible and tangible assets corresponds to the removal of Cellectis AB from the scope of consolidation following its sale in August 2014.

(2) The increase of operating receivables reflects primarily (i) the Research Credit Tax for 2013 which has been refunded in February 2015 and (ii) receivables from Pfizer and Lonza Biologics PLC.

(3) The increase in cash and cash equivalents is the consequence of (i) the payment by Servier of an upfront of €7.5million in February 2014, (ii) €20.5 million of share capital increase subscribed in March 2014 by U.S. Biotechnology Specialist Institutional Investors, (iii) an upfront payment of $80 million paid by Pfizer in August 2014 which in addition took a participation of 10% in Cellectis with a payment in cash of €25.8 million and (iv) a share capital increase of €13,4 million through the exercise of non-employees warrants issued in October 2011.

Balance sheet – Equity and liabilities

In thousands of euros	December 31, 2014	December 31, 2013
Share capital and share premium account	**193,301**	**135,378**
Reserves	(132,536)	(77,236)
Net profit (loss), Group share	20	(55,402)
Equity attributable to equity holders of the parent	60,786	2,740
Equity attributable to non-controlling interests	(1,259)	(223)
Total equity	**59,527**	**2,517**
Long-term debt	2,824	3,375
Non-current provisions	398	437
Total non-current liabilities	**3,222**	**3,812**
Short-term debt	862	691
Operating payables [1]	72,588	19,401
Current provisions [2]	1,415	2,454
Total current liabilities	**74,865**	**22,546**
TOTAL EQUITY AND LIABILITIES	**137,614**	**28,875**

(1) The increase of operating payables reflects the deferred income corresponding to the collaboration agreements concluded with Servier and Pfizer.

(2) Current provisions include €0.7 million for the Employment Protection Plans –PSE– launched at the end of 2013 and in 2014.

Income statement

In thousands of euros	2014	2013
Sales [1]	21,627	5,362
Other operating income [2]	4,826	7,362
Total revenue	**26,453**	**12,724**
Royalties expenses [3]	(3,035)	(542)
Research and development expenses	(14,407)	(17,844)
Selling, general and administrative expenses	(13,114)	(19,034)
Other operating income and expenses	(1,142)	(1,832)
Operating profit (loss)	**(5,245)**	**(26,528)**
Financial gain (loss)	**(7,095)**	**(312)**
Income (loss) from continuing operations	1,850	(26,839)
Loss from discontinued operations	(2,822)	(29,580)
NET LOSS	**(972)**	**(56,419)**

(1) The increase of €16.3 million reflects revenues of €2.9 million from Servier and €9.0 million from Pfizer, as well as revenues of €4.9 million from other licensees. The income was partially offset by the decrease of revenues from the Tools and Services segment.

(2) The decrease of €2.6 million primarily reflects the discontinuation of €1.7 million in research subsidies related to research programs that were terminated in 2013 and 2014.

(3) The increase of €2.5 million is due primarily to increased license and royalty payments following license agreements with Life Technologies and Institut Pasteur.

Cash flow statement

In thousands of euros	2014	2013
Net loss for the period	**(972)**	**(56,419)**
Including net loss for the period of discontinued operations	(2,822)	(29,580)
Net (loss) income for the period of continuing operations	1,850	(26,839)
Reconciliation of net loss and of the cash used for operating activities	(6,156)	5,019
Operating cash flows before change in working capital	(4,306)	(21,820)
Change in working capital	46,779	2,676
Cash flow provided by (used in) operating activities of continuing operations	42,473	(19,144)
Cash flow provided by (used in) operating activities of discontinued operations	(748)	291
Cash flows provided by (used in) operating activities	**41,725**	**(18,853)**
Cash flows from investment activities	**(1,353)**	**(459)**
Cash flows from financing activities [1]	**57,904**	**5,194**
(Decrease) increase in cash	**98,276**	**(14,197)**
Cash and cash equivalents at the beginning of the year	7,559	21,808
Effect of exchange rate changes on cash	6,511	(52)
Cash and cash equivalents at the end of the year	**112,347**	**7,559**
Cash from discontinued operations	-	1,290
Cash from continuing operations	112,347	6,269

(1) Our net cash flows provided by financing activities from continuing operations increased by €52.7 million from 2013 to 2014. The amount in 2014 includes proceeds from the issuance and sale of ordinary shares to institutional investors in March 2014, to Pfizer in July 2014, and in connection with the exercice of non-employees warrants in November 2014.

Stock price evolution and shareholder structure
As of December, 2014

Amid still challenging and volatile market conditions, the share price varied between €2.30 on January 2, 2014 and €14.58 on July 8, 2014 with its highest closing price being €14.00 on July 8 and its lowest being €2.40 on January 2. The daily average volume of shares traded was 220,804, 2.3 times the average recorded in 2013.



As of February, 2015

CORPORATE SOCIAL RESPONSIBILITY

Cellectis is focused on addressing the medical and food needs of an ever-growing global population through the use of proprietary gene-editing technologies. Leveraging the expertise of our management and clinical teams, we believe we can make strong advancements in the immuno-oncology and plant sciences fields.

Our Objective

Cellectis' mission is two-fold: develop treatments for historically incurable diseases and produce healthier food products to benefit the global population.

Cellectis' Ethics Charter

By signing the Group's Ethics Charter, each member of Cellectis commits to upholding its standards. For example, the values defended in this Charter cover the employee work conditions, as well as research objectives. Cellectis expects its associates, as well as its providers and subcontractors, to comply with this Charter in execution of their activities. They are also expected to respect human rights, labor rights, and the environment.

Access to training

Cellectis fosters the well-being and professional development of its team members, providing quality training programs tailored to each stage of an employee's career path. Through these structured learning opportunities, Cellectis strives to enable the career advancement of its employees.

Governance

Executive Committee

Dr André Choulika, Chief Executive Officer
André Choulika, Ph.D., is one of the founders of Cellectis and has been Chairman of the Board and Chief Executive Officer since 2000. He has also been President of Calyxt (previously Cellectis plant sciences) since August 2010. From 1997 to 1999, Dr Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children's Hospital, where he was a pioneer in the analysis and use of meganucleases to modify complex genomes. He has also served on the boards of directors of several biotechnology companies. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. Dr Choulika also has management training from the HEC (Challenge +).

Dr Philippe Duchateau, Chief Scientific Officer
Philippe Duchateau, Ph.D., joined Cellectis in 2001 to pioneer the field of gene editing. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur (Lille, France), he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco (United States) within the Cardiovascular Research Institute. He is co-inventor of numerous patents in the field of nucleases and gene editing and co-authors on more than 50 scientific publications and co-editor of one book entitled "Site-directed Insertion of Transgenes." As head of Cellectis' Research department since 2004, he helped to the development of Cellectis' technologies. Philippe Duchateau has served as Chief Scientific Officer since 2012.

Thierry Moulin, Chief Financial Officer
Thierry Moulin joined Cellectis as Chief Financial Officer in 2014. Thierry Moulin has been a partner at TMBB Consulting since 2008. He was also previously the Chief Financial Officer of Vergnet SA, Ermewa and Toshiba TEC and was a member of the board of directors of Vergnet SA. Mr. Moulin has specialized in the administrative and financial management of industrial groups in France, such as AIRSEC Industries and Süd-Chemie, as well as internationally, including in Japan from 1986 to 2008. He worked as an auditor from 1982 to 1986 after graduating from Rouen Business School.

Dr Mathieu Simon, Executive Vice President, Chief Operating Officer
Mathieu Simon, MD, has served as Executive Vice-President since 2012, and as Chief Operating Officer since 2013. Dr Simon has also been a member of Cellectis' board of directors since 2013. Prior to joining Cellectis, Dr Simon was Senior Vice President Head of Global Pharmaceutical Operations at Pierre Fabre SA. From 2000 to 2010, he was a Director of Wyeth S.p.A., Farmindustria, and Pharma in Italy. Dr Simon graduated from medical school at the University of Paris in 1982. Dr Simon today is an advisor at the European Commission D.G. Research and Innovation (Horizon 2020).

Dr David Sourdive, Executive Vice President Corporate Development
David Sourdive, Ph.D., is a co-founder of Cellectis and has held the position of Executive Vice President, Corporate Development since 2008. Dr Sourdive has also been a member of Cellectis' board of directors since 2000. Since 2014, Dr Sourdive has also served on the board of directors of Mediterranean Institute for Life Sciences. He previously served on the board of directors of Medicen Paris Region and Seine Saint Denis Avenir. From 1998 to 2000, he directed the biotechnologies laboratory of the Centre d'Etudes du Bouchet for the French Ministry of Defense. Dr Sourdive graduated from the École Polytechnique and received his Ph.D. in molecular virology at the Institut Pasteur. He also has management training from the HEC (Challenge +).

Board of Directors

Dr André Choulika, Ph.D., Chairman

Laurent Arthaud, Director
Laurent Arthaud has served as a member of Cellectis' board of directors since 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement (formerly CDC Enterprises, a subsidiary of Caisse des Dépôts) since 2012. From 2006 to 2012, Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Since 2009 he has also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. From 1999 to 2004 he served as Vice President of Aventis Capital, an investment subsidiary of the pharmaceuticals group Aventis, and as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud is a graduate of the École Polytechnique and the l'École Nationale de Statistique et d'Administration Économique.

Pierre Bastid, Director
Pierre Bastid has served as a member of Cellectis' board of directors since 2011. He has been a member of the board of directors of HOUGOU S.A. since 2011. He also currently serves on the boards of directors of HOUGOU Développement S.A., Louise 342-344 S.A., Crystal Sunrise S.A., Shango S.A., Hebioso S.A., Les Bastidons S.A., Nepteam S.A.S., Krishna S.C. and La Chartreuse B S.C. From 2005 to 2011, he served as the President and Chief Executive Officer of Converteam Group S.A.S. (formerly Alstom Power Conversion). From June 2011 to July 2014, he was also a member of board of directors of Zaka S.A. From 2008 to 2011, Mr. Bastid served as President and a member of the board of directors of CVT Holding S.A.S. and as President of Financière CVT S.A.S. From 2009 to 2011, he served as President of CMC Kilimanjaro, CMC Everest, CMC Mac Kinley, CMC Elbrouz and CMC K2.

Alain Godard, Independent Director
Mr. Godard is a graduate of the École Nationale Supérieure Agronomique de Toulouse. He began his agronomy career in 1967 in Africa as a researcher at the l'Institut de Recherche pour les Huiles et Oléagineux (institute for research on oils and oleaginous plants). He has served as a member of Cellectis' board of directors since October 2007. Since 2002, Mr. Godard has been a consultant in plant biotechnology and management. He has been the Chief Executive Officer of SARL Godard & Co. since June 2009, and he also serves on the board of directors of Fermentalg SA. He previously served as chairman of the management board of Aventis Cropscience from 1999 to 2001 and served on the executive committee of Aventis Cropscience for the same period. He held several executive positions at Rhône-Poulenc Agrochimie since joining in 1975, and he became CEO of the company in 1991 and chairman and CEO in 1995. Mr. Godard was appointed to the executive committee of the Rhône-Poulenc group in 1997, where he oversaw operations in the field of animal and plant health and the group's Asia region. In 1999 he was an active player in the merger of Hoechst and Rhône-Poulenc, which resulted in the founding of Aventis.

Dr Annick Schwebig, Director
Annick Schwebig, MD, has served as a member of Cellectis' board of directors since 2011. In 2000, she founded the French subsidiary of Actelion, of which she is the General Manager. Actelion is a biopharmaceuticals company specializing in innovative treatments to serve unmet medical needs. She is also President of the Biotechnologies Committee within the LEEM (French Pharmaceutical Industry Association's) since 2000, which coordinates studies on cell therapies and nanomedicine, as well as General Secretary of the Alliance for Research and Innovation in Health Industries (ARIIS). A graduate of the University of Paris medical school, Dr Schwebig worked as a senior manager at the biopharmaceuticals company Bristol-Myers Squibb for 17 years from 1983 to 2000.

Dr Mathieu Simon, MD, Director

Dr David Sourdive, Ph.D., Director

Committees of the Board of Directors

Audit and Finance committee
Laurent Arthaud, Director
Pierre Bastid, Director

Compensation Committee
Alain Godard, Independent Director
Dr Annick Schwebig, Director

External Auditors

Statutory Auditors
Ernst & Young
JMH Conseils

Alternate Auditors
Auditex
Georges Ray Conseils

Cellectis
8 rue de la Croix Jarry - 75013 Paris - France
430 East 29th Street - New York, NY 10016 - USA
e-mail: media@cellectis.com
website: www.cellectis.com

Photo credits
Ramon Martinez
Cellectis
IStock

Graphic designers
Avantmidi.fr agency
Cover: Valentina Herrmann